Peptide Comparison
Semaglutide vs Orforglipron
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Semaglutide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Semaglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Semaglutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Semaglutide | Orforglipron | |
|---|---|---|
| Class | GLP-1 receptor agonist | Oral non-peptide GLP-1 agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion [1][2] | Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14] |
| Route | SC injection / Oral | Oral |
| Half-life | ~7 days | ~29-49 hrs |
| Dosage (research) | 0.25 mg SC weekly (Wegovy/Ozempic label starting dose, escalate monthly to label max 2.4 mg weekly per STEP-1 protocol) [1][2][3]; oral 3 mg daily Rybelsus starting dose (target 14 mg daily) | 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15] |
| Evidence tier | FDA-Approved | FDA-Approved |
| Research depth | 258 indexed | 157 indexed |
| Availability | Prescription | Prescription |
| Reported risks | Nausea; vomiting; constipation; pancreatitis; gallbladder disease; thyroid C-cell tumor warning [1][2] | GI effects; hepatic enzyme elevations |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Semaglutide or Orforglipron?
Semaglutide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Semaglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Semaglutide's evidence base is currently denser.
What is the difference between Semaglutide and Orforglipron?
Semaglutide is classed as GLP-1 receptor agonist; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: Semaglutide, GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: Semaglutide, ~7 days; Orforglipron, ~29-49 hrs. Routes in published studies: Semaglutide, SC injection / Oral; Orforglipron, Oral.
Which has stronger evidence, Semaglutide or Orforglipron?
Semaglutide and Orforglipron sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Semaglutide is graded FDA-Approved, with 70 cited sources on its reference page and 258 indexed studies. Orforglipron is graded FDA-Approved, with 32 cited sources on its reference page and 157 indexed studies.
Which is more accessible, Semaglutide or Orforglipron?
Both Semaglutide and Orforglipron are FDA-approved drugs. Catalog status: Semaglutide, Prescription; Orforglipron, Prescription.
Are Semaglutide and Orforglipron ever combined?
Semaglutide and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…